Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN ISIN · CA3978841078 CSE Human health and social work activities
Open in API
Filings indexed 579 across all filing types
Latest filing 2021-03-01 Board/Management Inform…
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing appointments of new senior management positions (Vice President, Research & Operations and Chief Medical Officer) and the stepping down of a Chief Science Officer. It focuses on changes in the company's board or senior management personnel. There is no financial data, no mention of financial results, no regulatory filings or report publications, and no other types of corporate actions such as mergers, dividends, or share transactions. The content clearly fits the category of announcements related to changes in the company's board or senior management.
2021-03-01 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'NI 43-101 TECHNICAL REPORT FOR THE PEÑASCO QUEMADO SILVER PROPERTY' with a report date and effective date of November 20, 2020. NI 43-101 is a Canadian mineral resource classification standard for technical reports on mineral properties. The content includes detailed sections such as property description, exploration history, geological setting, drilling, mineral resource and reserve estimates, mining methods, economic analysis, environmental studies, and recommendations. The length is substantial (15,000 characters) and contains comprehensive technical and geological data, typical of a formal technical report rather than a brief announcement or summary. This type of document is a specialized technical report related to mining properties and resource estimation, which does not fit into typical financial report categories like Annual Report, Earnings Release, or Management Reports. Given the specificity and nature of the document, it aligns best with the category of Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not neatly fit into other categories. It is not an announcement or certification but a full technical report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-02-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Algernon Pharmaceuticals has awarded a manufacturing contract to Dalton Pharma for their stroke program involving DMT. It discusses the background of DMT, preclinical study results, and company information. There are no financial statements, regulatory filings, voting results, or management changes. The content is primarily a corporate announcement about a contract award and research program progress, not a financial report, regulatory filing, or meeting material. Therefore, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2021-02-19 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing that Algernon Pharmaceuticals is considering adding lung scarring as an additional endpoint in its Phase 2b/3 COVID-19 study protocol. It discusses clinical trial protocol adjustments and provides background on the company and forward-looking statements. There are no financial statements, regulatory filings, voting results, or detailed financial data. The content is an update on clinical study protocol and company plans, typical of a Capital/Financing Update or general corporate announcement. However, since it relates to clinical trial protocol changes and not fundraising or capital structure changes, it does not fit CAP. It is not a report or presentation but a news announcement. Given the options, the best fit is Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other categories.
2021-02-11 English
Decision Document (Preliminary).pdf
Regulatory Filings Classification · 100% confidence The document is a receipt issued by the British Columbia Securities Commission and Ontario Securities Commission for a Preliminary Short Form Base Shelf Prospectus filed by Algernon Pharmaceuticals Inc. It is a regulatory acknowledgment of the filing of a prospectus, not the prospectus itself or a financial report. The document is short (1173 characters) and serves as an official receipt rather than containing financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-02-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Algernon Pharmaceuticals has signed an agreement with Charles River Laboratories for preclinical studies of DMT related to stroke clinical research. It describes the nature of the agreement, background on DMT, and the scientific rationale for the research. There are no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or governance reports. The document is an announcement of a business development related to research collaboration, not a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or business update that does not fit other categories, which corresponds to Regulatory Filings (RNS). The document length is 8582 characters, which is substantial but the content is clearly an announcement rather than a report or transcript.
2021-02-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.